CVS Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık

03
Fiyat $86.46
Piyasa Değeri (MRQ) $110.50B
P/E (TTM) 22.8
Hisse Başına Kâr (TTM) $3.79
Gelir (TTM) $415.09B
Temettü Verimi 3.1%
ROE (TTM) 6.2%
D/E Borç/Özsermaye 0.0
52 Haftlık Aralık $70–$111

CVS Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin

04
aralık
çubuklar

Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.

Hisse bölünmeleri 4
Ex-tarihi Bölünme Tür
07 Haziran 2005 2-for-1 İleri
16 Haziran 1998 2-for-1 İleri
15 Mart 1989 2-for-1 İleri
03 Mayıs 1983 2-for-1 İleri

CVS Health Corporation Common Stock Hakkında Wikipedia'dan şirket genel bakışı

05 · wikidata

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

History

1960s

The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.

1970s

By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.

1980s

In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.

1990s

CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.

In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.

2000s

In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.

2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.

2010s

2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.

CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.

2020s

In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.

On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.

Finances

Subsidiaries and assets

Aetna

Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.

CVS Pharmacy

CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.

MinuteClinic

MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.

CVS Caremark

CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.

CVS Media Exchange

CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.

CVS Specialty

CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.

Longs Drugs

Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.

Navarro Discount Pharmacies

Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.

Accordant

Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.

Coram

Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

Omnicare

Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

HealthHUB

HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.

Store brands and private label brands

CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.

Criticism and controversy

Health and Medicare fraud

In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.

The combined price to settle this dispute with the U.S. Government cost the company over $250 million.

Elensys

In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.

Trio Drugs Lawsuit

On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.

Boston prescriptions

During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.

Restatements

On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.

On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.

Pharmaceutical kickbacks

In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.

The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.

There was no admission of wrongdoing by Caremark or AdvancePCS.

CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.

Deceptive business practices

In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:

CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).

However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).

...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).

Rhode Island Senate corruption case

In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."

Privacy violations

On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).

In September 2026, CVS entered into a $20.5 million class action settlement after a lawsuit alleged that CVS disclosed customers' personal data to advertising company Criteo.

Business practices under investigation

On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.

DEA investigation into oxycodone diversion

According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".

FTC charges of deceptive pricing

On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.

Co-responsibility for opioid crisis

In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.

In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.

In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.

CFI lawsuit for consumer fraud

In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.

Abortion pill controversy

In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.

Pharmacists mistakenly cause an abortion

In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."

At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.

Animal welfare

In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.

Community involvement and philanthropy

Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.

Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.

In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).

Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗

Wikidata ↗

sektörHealth Care endüstriHealth Care çalışanlar219.000 ülkeUS

10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri

06
Gelir$402.07B
2017-12-31 → 2025-12-31
Hisse Başına Kâr$1.39
2017-12-31 → 2025-12-31
Serbest Nakit Akışı$7.81B
2017-12-31 → 2025-12-31
Net kar marjı1.2%
2017-12-31 → 2025-12-31
Değerleme ve Oranlar 07–12

Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?

Metrik 5 Yıllık trend CVS 5Y ort. Akran Ortalaması Sonuç
P/E (TTM) 22.85Y ort. ≈25.5 ≈25.5 23.3 Aşırı değerli
F/S (TTM) 0.35Y ort. ≈0.3 ≈0.3 1.3 Düşük değerli
F/D (MRQ) 1.45Y ort. ≈1.4 ≈1.4 2.9 Düşük değerli
EV / EBITDA 10.75Y ort. ≈6.1 ≈6.1 11.4 Düşük değerli
Fiyat / Serbest Nakit Akışı (TTM) 9.45Y ort. ≈9.9 ≈9.9 · ·
Fiyat / Nakit Akışı (TTM) 7.55Y ort. ≈7.6 ≈7.6 9.8 Adil değer
EV / Revenue (EV / Gelir) 0.25Y ort. ≈0.2 ≈0.2 · ·
EV / FCF 12.75Y ort. ≈9.3 ≈9.3 · ·
Fiyat / Maddi Defter Değeri (MRQ) 2.0 · · ·

Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.

değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme

Temettüler Temettü verimi, ödeme oranı, temettü geçmişi, 5 Yıllık CAGR

13
Temettü Verimi3.1%
Temettü Ödeme Oranı192.1%
Yıllıklaştırılmış Ödeme≈$2.66Üç Aylık Ödeme
5 Yıllık Temettü CAGR≈5.9%Hisse başına, bölünmeye göre ayarlanmış
Ex-tarihiMiktarPara BirimiTemettü Verimi
Tem 23, 2026$0,67USD≈2.5%
Nis 23, 2026$0,67USD≈3.4%
Oca 22, 2026$0,67USD≈3.2%
Eki 23, 2025$0,67USD≈3.3%
Tem 22, 2025$0,67USD≈4.4%
Nis 22, 2025$0,67USD≈4.1%
Oca 23, 2025$0,67USD≈4.9%
Eki 21, 2024$0,67USD≈4.6%
Tem 22, 2024$0,67USD≈4.5%
Nis 19, 2024$0,67USD≈3.6%
Oca 19, 2024$0,67USD≈3.4%
Eki 19, 2023$0,61USD≈3.4%
Tem 20, 2023$0,61USD≈3.2%
Nis 20, 2023$0,61USD≈3.2%
Oca 19, 2023$0,61USD≈2.6%
Eki 20, 2022$0,55USD≈2.4%
Tem 21, 2022$0,55USD≈2.3%
Nis 21, 2022$0,55USD≈2.0%
Oca 20, 2022$0,55USD≈2.0%
Eki 21, 2021$0,50USD≈2.3%

Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi

14
Ort. Sürpriz 22.0%
Sonraki Rapor Eki 27, 2026
DönemRaporEPS GerçekEPS TahminSürpriz
30 Haziran 2026 Tem 29, 2026 $2.58 $1.87 38.0%
31 Mart 2026 $2.57 $2.22 15.8%
31 Aralık 2025 $1.09 $1.00 8.8%
30 Eylül 2025 $1.60 $1.38 15.7%
30 Haziran 2025 $1.81 $1.47 23.0%
31 Mart 2025 $2.25 $1.72 30.8%

Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı

15
Gelir Tablosu 16
Metrik Eğilim 20252024202320222021202020192018201720162015
Revenue $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Cost of Revenue $221.17B$206.29B$217.10B$196.89B$175.80B$163.98B$158.72B·$153.45B$146.53B$126.76B
Gross Profit ········$28.55B$28.86B$26.53B
Operating Expenses $397.41B$364.29B$344.03B$314.51B$278.80B$254.79B$244.79B·$18.81B$18.45B$17.05B
Operating Income $4.66B$8.52B$13.74B$7.95B$13.31B$13.91B$11.99B·$9.54B$10.39B$9.47B
Interest Expense ··$2.66B$2.29B$2.50B$2.91B$3.04B·$1.06B$1.08B$859M
Interest Income ········$21M$20M$21M
Other Non-op $112M$99M$88M$169M$182M$206M$124M·$-208M$-28M·
Pretax Income $2.14B$6.15B$11.17B$5.84B$10.54B$9.77B$9.00B·$8.27B$8.64B$8.62B
Income Tax $408M$1.56B$2.81B$1.51B$2.55B$2.57B$2.37B·$1.64B$3.32B$3.39B
Net Income $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
EPS (Basic) $1.40$3.67$6.49$3.29$6.07$5.48$5.10·$6.47$4.93$4.66
EPS (Diluted) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Shares (Basic) 1,267,000,0001,259,000,0001,285,000,0001,312,000,0001,319,000,0001,309,000,0001,301,000,000·1,020,000,0001,073,000,0001,118,000,000
Shares (Diluted) 1,271,000,0001,262,000,0001,290,000,0001,323,000,0001,329,000,0001,314,000,0001,305,000,000·1,024,000,0001,079,000,0001,126,000,000
EBITDA $9.27B$13.11B$18.11B$11.99B$17.70B$18.35B$16.36B·$12.00B$10.34B$9.45B
Bilanço 31
Metrik Eğilim 20252024202320222021202020192018201720162015
Cash & Equivalents $8.45B$8.59B$8.20B$12.95B$9.41B$7.85B$5.68B·$1.70B$3.37B$2.46B
Short-term Investments $2.15B$2.41B$3.26B$2.78B$3.12B$3.00B$2.37B·$111M$87M$88M
Receivables $39.78B$36.47B$35.23B$27.28B$24.43B$21.74B$19.62B·$13.18B$12.16B$11.89B
Inventory $19.25B$18.11B$18.02B$19.09B$17.76B$18.50B$17.52B·$15.30B$14.76B$14.00B
Other Current Assets $5.09B$3.08B$3.15B$2.64B$5.29B$5.28B$5.11B$4.53B$945M$660M$722M
Current Assets $74.71B$68.64B$67.86B$65.63B$60.01B$56.37B$50.30B$45.20B$31.23B$31.04B$29.16B
PP&E (Net) ···$12.87B$12.90B$12.61B$12.04B$11.36B$10.29B$10.18B$9.86B
PP&E (Gross) ···$34.60B$33.55B$31.31B$28.93B·$24.29B$22.80B$21.04B
Accum. Depreciation ···$21.48B$20.65B$18.70B$16.89B·$14.00B$12.63B$11.18B
Goodwill $85.48B$91.27B$91.27B$78.15B$79.12B$79.55B$79.75B·$38.45B$38.25B$38.11B
Intangibles $25.51B$27.32B$29.23B$24.80B$29.03B$31.14B$33.12B$36.31B$13.63B$13.51B$13.88B
Other Non-current Assets $7.11B$4.79B$4.66B$4.62B$4.71B$4.62B$4.60B$4.53B$1.42B$1.49B$1.44B
Total Assets $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B$216.67B$95.13B$94.46B$92.44B
Accounts Payable ········$8.86B$7.95B$7.49B
Accrued Liabilities $22.39B$20.81B$23.52B$18.75B$17.67B$14.24B$12.13B$10.66B$6.58B$6.94B$6.83B
Short-term Debt $0$2.12B$200M$0·$0$0·$1.28B$1.87B$0
Current Liabilities $88.69B$84.61B$79.19B$69.42B$67.81B$62.02B$53.30B$45.76B$30.65B$26.25B$23.17B
Capital Leases $13.64B$14.90B$16.03B$16.80B$18.18B$18.76B$18.93B$18.83B$306M··
Deferred Tax $3.83B$3.81B$4.31B$4.02B$6.27B$6.79B$7.29B$7.74B$3.00B$4.21B$4.22B
Other Non-current Liabilities $6.77B$5.43B$6.21B$6.73B$1.90B$2.35B$2.16B$2.26B$1.28B$1.55B$1.54B
Total Liabilities $178.16B$177.49B$173.09B$156.51B$157.62B$161.01B$158.28B$157.95B$57.44B··
Long-term Debt ······$68.48B$72.61B$27.00B$25.70B$27.50B
Total Debt $0$2.12B$200M···$3.78B·$27.00B$27.53B$27.46B
Common Stock ·$18M$18M$18M$17M$17M$17M·$17M$17M$17M
Paid-in Capital ········$32.08B$31.62B$30.95B
Retained Earnings $61.20B$62.84B$61.60B$56.40B$54.91B$49.64B$45.11B$41.09B$43.56B$38.98B$35.51B
Treasury Stock $36.79B$36.82B$33.84B$31.86B$28.17B$28.18B$28.23B·$37.80B$33.45B$28.89B
AOCI $406M$-120M$-297M$-1.26B$965M$1.41B$1.02B·$-165M$-305M$-358M
Stockholders' Equity $75.21B$75.56B$76.46B$71.47B$75.08B$69.39B$63.86B$58.40B$37.69B$36.83B$37.20B
Liabilities + Equity $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B·$95.13B$94.46B$92.44B
Shares Outstanding 1,271,000,0001,260,000,0001,288,000,0001,300,000,0001,322,000,0001,310,000,0001,302,000,000·1,712,000,0001,061,000,0001,101,000,000
Nakit Akışı 19
Metrik Eğilim 20252024202320222021202020192018201720162015
D&A $4.61B$4.60B$4.37B$4.22B$4.49B$4.44B$4.37B·$2.48B$2.48B$2.09B
Stock-based Comp $535M$540M$588M$447M$484M$400M$453M·$234M$222M$230M
Deferred Tax $102M$-572M$-676M$-2.03B$-402M$-564M$-649M·$-1.42B$3M$-234M
Amort. of Intangibles $2.00B$2.00B$1.90B$1.80B$2.20B$2.30B$2.40B·$817M$795M$611M
Restructuring ········$215M··
Other Non-cash $3.63B$-72M$804M$9.41B$5.79B$4.41B$2.04B·$93M··
Operating Cash Flow $10.64B$9.11B$13.43B$16.18B$18.27B$15.87B$12.85B·$8.01B$10.14B$8.54B
CapEx $2.83B$2.78B$3.03B$2.73B$2.52B$2.44B$2.46B·$1.92B$2.22B$2.37B
Investing Cash Flow $-5.87B$-7.61B$-20.89B$-5.05B$-5.26B$-5.53B$-3.34B·$-2.88B$-2.47B$-13.42B
Debt Issued $3.97B$7.91B$10.90B$0$987M$9.96B$3.74B·$0$3.46B$14.80B
Net Debt Issued $340M$3.14B$7.73B$-4.21B$-9.27B$-5.67B$-4.60B··$-2.49B$11.90B
Stock Repurchased $0$3.02B$2.01B$3.50B$0$0$0·$4.36B$4.46B$5.00B
Net Stock Activity $0$-3.02B$-2.01B$-3.50B··$0·$-4.36B$-4.46B$-5.00B
Dividends Paid $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B
Financing Cash Flow $-4.94B$-1.14B$2.68B$-10.52B$-11.36B$-7.70B$-7.65B·$-6.75B$-6.76B$4.88B
Net Change in Cash $-172M$359M$-4.78B$614M$1.65B$2.63B$1.85B·$-1.62B$912M$-22M
Taxes Paid $2.17B$1.70B$3.52B$4.12B$3.19B$2.93B$2.72B·$2.91B$3.06B$3.27B
Free Cash Flow $7.81B$6.33B$10.39B$13.45B$15.74B$13.43B$10.39B·$6.09B$7.84B$6.04B
Levered FCF ··$8.40B$11.76B$13.85B$11.29B$8.15B·$5.24B$7.18B$5.52B
Kârlılık 8
Metrik Eğilim 20252024202320222021202020192018201720162015
Gross Margin ········15.4%16.3%17.3%
Operating Margin 1.2%2.3%3.8%2.4%4.5%5.2%4.7%·5.1%5.8%6.2%
Net Margin 0.44%1.2%2.3%1.3%2.7%2.7%2.6%·3.6%3.0%3.4%
Pretax Margin 0.53%1.7%3.1%1.8%3.6%3.6%3.5%·4.5%4.9%5.6%
EBITDA Margin 2.3%3.5%5.1%3.7%6.1%6.8%6.4%·6.5%5.8%6.2%
ROA 0.70%1.8%3.5%1.8%3.4%3.2%3.0%·7.0%5.7%6.2%
ROE 2.4%6.1%11.3%5.7%10.9%10.8%10.8%·17.8%14.4%13.9%
ROIC 5.0%8.2%13.4%8.1%13.3%14.8%13.1%·11.8%9.9%8.9%
Likidite ve Solventlik 5
Metrik Eğilim 20252024202320222021202020192018201720162015
Current Ratio 0.80.80.90.90.90.90.9·1.01.21.3
Quick Ratio 0.60.60.60.60.50.50.5·0.50.60.6
Debt / Equity 0.00.00.0···0.1·0.70.70.7
LT Debt / Equity ········0.60.70.7
Interest Coverage ··5.23.45.34.83.9·9.09.611.0
Verimlilik 3
Metrik Eğilim 20252024202320222021202020192018201720162015
Asset Turnover 1.61.51.51.41.31.21.2·1.91.91.8
Inventory Turnover 11.811.411.710.79.79.19.3·10.410.39.8
Receivables Turnover 10.510.411.412.512.713.013.8·14.614.814.2
Hisse Başına 7
Metrik Eğilim 20252024202320222021202020192018201720162015
Book Value / Share $59.18$59.97$59.36$54.63$56.79$52.97$49.05·$37.17$34.71$33.78
Revenue / Share $316.34$295.41$277.35$243.74$219.80$204.49$196.76·$180.43$164.53$136.14
Cash Flow / Share $8.37$7.22$10.41$12.23$13.74$12.07$9.85·$7.82$9.33$7.47
Cash / Share $6.65$6.81$6.36$9.96$7.12$6.00$4.36·$1.67$3.18$2.23
Dividend / Share $2.66$2.66$2.42$2.20$2.00$2.00$2.00·$2.00$1.70$1.40
Dividend Paid / Share ········$2.00··
EPS (TTM) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Büyüme Oranları 10
Metrik Eğilim 20252024202320222021202020192018201720162015
Revenue YoY 7.8%4.2%10.9%10.4%8.7%······
Revenue CAGR 3Y 7.6%8.5%10.0%········
Revenue CAGR 5Y 8.4%··········
EPS YoY -62.0%-43.4%98.5%-45.9%10.3%······
EPS CAGR 3Y -24.7%-15.3%5.8%········
EPS CAGR 5Y -23.9%··········
Net Income YoY -61.7%-44.7%93.5%-46.1%11.5%······
Net Income CAGR 3Y -25.7%-16.8%5.1%········
Net Income CAGR 5Y -24.4%··········
Dividends Paid CAGR 5Y 5.3%··········
Değerleme (TTM) 16
Metrik Eğilim 20252024202320222021202020192018201720162015
Revenue TTM $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Net Income TTM $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
Market Cap $100.87B$56.56B$101.70B$121.15B$136.38B$89.47B$96.73B·$73.52B$83.72B$107.64B
Enterprise Value $90.27B$47.69B$90.45B···$92.45B·$98.71B$107.80B$132.56B
P/E 57.112.312.228.617.112.514.6·11.316.121.1
P/S 0.30.20.30.40.50.30.4·0.40.50.7
P/B 1.30.71.31.71.81.31.5·2.02.32.9
P / Cash Flow 9.56.27.67.57.55.67.5·9.28.312.8
P / FCF 12.98.99.89.08.76.79.3·12.110.717.8
EV / EBITDA 9.73.65.0···5.7·8.210.414.0
EV / FCF 11.67.58.7···8.9·16.213.721.9
EV / Revenue 0.20.10.3···0.4·0.50.60.9
Dividend Yield 3.4%6.0%3.1%2.4%1.9%2.9%2.7%·2.8%2.2%1.5%
Earnings Yield 1.8%8.2%8.2%3.5%5.8%8.0%6.8%·8.9%6.2%4.7%
Payout Ratio 192.1%73.1%37.5%70.1%33.2%36.5%39.2%·30.9%34.6%30.1%
Annual Payout $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B

En son dönem solda · null değerler · olarak gösterilir

Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Gelir $402.07B $372.81B $357.78B $322.47B $292.11B
Faaliyet Kâr Marjı % 1.2% 2.3% 3.8% 2.4% 4.5%
Net Gelir $1.77B $4.61B $8.34B $4.31B $8.00B
Seyreltilmiş Hisse Başı Kâr $1.39 $3.66 $6.47 $3.26 $6.02

Kurumsal Sahipler (13F) 2.274 dosya · $125.7B toplam · Tarih itibarıyla 30 Eylül 2026

17

Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.

Sahipler 2.274
Tutulan Değer $125.7B
Yeni pozisyonlar 314
Çıkan pozisyonlar 93
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
Yeni pozisyonlar Çıkan pozisyonlar Artırıldı Azaldı Net hisse senedi değişimi
314 (+117 önceki Ç'ye göre) 93 (-96 önceki Ç'ye göre) 799 (+75 önceki Ç'ye göre) 755 (-20 önceki Ç'ye göre) +50.0M

Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.

Kurum Değer Hisse senetleri % izlenen 13F'nin Tür
BlackRock, Inc. $12.747.461.705 123.223.409 10,14% Hisse senetleri
VANGUARD GROUP INC $9.579.508.282 120.709.530 7,62% Hisse senetleri
VANGUARD CAPITAL MANAGEMENT LLC $8.618.974.924 83.315.369 6,86% Hisse senetleri
Capital World Investors $7.753.834.783 74.951.955 6,17% Hisse senetleri
STATE STREET CORP $6.236.318.558 60.283.408 4,96% Hisse senetleri
Dodge & Cox $5.173.820.539 50.012.765 4,12% Hisse senetleri
WELLINGTON MANAGEMENT GROUP LLP $3.496.725.140 33.801.113 2,78% Hisse senetleri
GEODE CAPITAL MANAGEMENT, LLC $3.079.404.427 29.899.653 2,45% Hisse senetleri
FMR LLC $2.991.837.927 28.920.617 2,38% Hisse senetleri
VANGUARD PORTFOLIO MANAGEMENT LLC $2.755.624.444 26.637.259 2,19% Hisse senetleri
Capital Research Global Investors $2.516.851.376 24.329.151 2,00% Hisse senetleri
BANK OF AMERICA CORP /DE/ $2.398.868.007 23.188.670 1,91% Hisse senetleri
JPMORGAN CHASE & CO $2.290.461.677 22.112.970 1,82% Hisse senetleri
Invesco Ltd. $2.130.597.379 20.595.431 1,70% Hisse senetleri
MORGAN STANLEY $1.924.793.937 18.606.028 1,53% Hisse senetleri
NORGES BANK $1.866.126.481 18.038.922 1,49% Hisse senetleri
Capital International Investors $1.591.868.430 15.387.600 1,27% Hisse senetleri
GOLDMAN SACHS GROUP INC $1.387.451.459 13.411.807 1,10% Hisse senetleri
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $1.371.677.011 13.259.314 1,09% Hisse senetleri
Davis Selected Advisers $1.227.594.458 11.865.916 0,98% Hisse senetleri
PZENA INVESTMENT MANAGEMENT LLC $1.217.558.500 11.769.536 0,97% Hisse senetleri
NORTHERN TRUST CORP $1.186.760.815 11.471.830 0,94% Hisse senetleri
FRANKLIN RESOURCES INC $1.032.982.350 9.985.330 0,82% Hisse senetleri
Legal & General Group Plc $948.946.746 9.172.999 0,76% Hisse senetleri
Bank of New York Mellon Corp $932.453.862 9.013.571 0,74% Hisse senetleri
Clearbridge Investments, LLC $883.116.767 8.536.952 0,70% Hisse senetleri
ROYAL BANK OF CANADA $880.475.000 8.511.113 0,70% Hisse senetleri
GQG Partners LLC $822.989.370 7.955.411 0,65% Hisse senetleri
AMERIPRISE FINANCIAL INC $821.911.618 7.943.034 0,65% Hisse senetleri
Amundi $778.468.900 7.525.080 0,62% Hisse senetleri
DIMENSIONAL FUND ADVISORS LP $763.688.490 7.381.983 0,61% Hisse senetleri
VANGUARD FIDUCIARY TRUST CO $741.242.940 7.165.229 0,59% Hisse senetleri
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $595.969.397 8.298.098 0,47% Hisse senetleri
Nuveen, LLC $544.750.652 5.265.836 0,43% Hisse senetleri
UBS Group AG $544.267.107 5.261.161 0,43% Hisse senetleri
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $524.415.257 5.069.263 0,42% Hisse senetleri
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $511.339.969 4.942.871 0,41% Hisse senetleri
GLENVIEW CAPITAL MANAGEMENT, LLC $499.125.457 4.824.799 0,40% Hisse senetleri
CITADEL ADVISORS LLC $497.856.229 4.812.530 0,40% Hisse senetleri
DEUTSCHE BANK AG\ $466.633.571 4.510.716 0,37% Hisse senetleri
RAYMOND JAMES FINANCIAL INC $449.870.951 4.348.680 0,36% Hisse senetleri
SUSQUEHANNA INTERNATIONAL GROUP, LLP $409.796.485 3.961.300 0,33% Alım opsiyonu
Allianz Asset Management GmbH $391.245.314 3.781.975 0,31% Hisse senetleri
WELLS FARGO & COMPANY/MN $380.921.357 3.682.178 0,30% Hisse senetleri
VIKING GLOBAL INVESTORS LP $378.974.695 3.663.361 0,30% Hisse senetleri
Swiss National Bank $371.195.152 3.588.160 0,30% Hisse senetleri
National Pension Service $352.166.145 3.404.216 0,28% Hisse senetleri
Mitsubishi UFJ Asset Management Co., Ltd. $322.653.390 3.118.927 0,26% Hisse senetleri
Russell Investments Group, Ltd. $312.682.898 3.022.292 0,25% Hisse senetleri
Holocene Advisors, LP $310.524.210 3.001.684 0,25% Hisse senetleri

Tüm 2.274 kurumsal sahibi göster →

Aktivistler ve %5+ sahipler 1 pozisyon

18

SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.

Başvuru sahibi Dosyalandı Hisse Durum Amaç Başvuru
CVS Caremark Corporation 07 Ocak 2011 · İlk başvuru M&A / satış SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Şirket yöneticileri 86 içeriden öğrenenler · 48 yöneticiler · 41 yönetim kurulu üyeleri

19
İçeriden Öğrenen Rol Son işlem Sahip olunan hisse senetleri Alımlar 12ay Satışlar 12ay Net 12ay
David J. Joyner President, CEO and Chair 01 Nisan 2026 F 70.349 0 0 $0
Karen S Lynch President and CEO 01 Nisan 2024 A 74.687 0 0 $0
Brian Newman EVP, Chief Financial Officer 31 Mayıs 2026 F 3.008 0 0 $0
Thomas F. Cowhey EVP and CFO 01 Nisan 2025 A 41.109 0 0 $0
Shawn M Guertin EVP & Chief Financial Officer 01 Nisan 2023 A 34.706 0 0 $0
Eva C Boratto EVP & CFO 04 Mayıs 2021 S 115.331 0 0 $0
David M Denton EVP and CFO 29 Kasım 2018 S 403 0 0 $0
David B Rickard Chief Financial Officer 14 Aralık 2009 M 207.179 0 0 $0
Howard A Mclure President, Caremark Pharm Serv 02 Kasım 2009 M 0 0 0 $0
Jonathan C Roberts EVP & Chief Operating Officer 01 Nisan 2022 A 426.025 0 0 $0
James David Clark SVP, Cont & Chief Acct Officer 26 Haziran 2026 F 27.606 0 0 $0
Amy Compton-Phillips EVP, Chief Medical Officer 31 Mayıs 2026 F 9.557 0 0 $0
Tilak Mandadi EVP, Chief Exp & Tech Officer 08 Mayıs 2026 S 10.133 0 1 $-6.230.379
Prem S Shah EVP and Group President 31 Mart 2026 A 64.356 0 0 $0
Heidi B Capozzi EVP and Chief People Officer 31 Mart 2026 A 13.023 3 0 $4.588
Samrat S. Khichi EVP, CPO and General Counsel 31 Mart 2026 A 33.421 0 0 $0
Steven H Nelson EVP and President, Aetna 31 Mart 2026 A 2.900 1 0 $1.289
Sreekanth K Chaguturu EVP and Chief Medical Officer 01 Nisan 2024 A 23.666 0 0 $0
Laurie P. Havanec EVP and Chief People Officer 01 Nisan 2024 A 9.426 0 0 $0
Brian A Kane EVP/President, Aetna 01 Nisan 2024 A 12.569 0 0 $0
Finke Daniel P EVP/Pres, Health Care Benefits 01 Nisan 2023 A 35.068 0 0 $0
Michelle A Peluso EVP and Co-President of Retail 01 Nisan 2023 A 124.383 0 0 $0
Thomas M Moriarty EVP & General Counsel 31 Aralık 2022 F 315.273 0 0 $0
Alan Lotvin EVP&President-PharmacyServices 04 Ağustos 2022 M 109.183 0 0 $0
Troyen A Brennan EVP and Chief Medical Officer 03 Nisan 2022 F 232.676 0 0 $0
Neela Montgomery EVP and Pres., Pharmacy/Retail 01 Nisan 2021 A 29.502 0 0 $0
Lisa Bisaccia Former EVP & Chief HR Officer 01 Nisan 2021 F 66.417 0 0 $0
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL 28 Şubat 2021 F 25.657 0 0 $0
Jonathan E. Mayhew EVP - Transformation 02 Aralık 2020 F 6.855 0 0 $0
Derica W Rice EVP & President, CVS Caremark 28 Şubat 2020 F 26.827 0 0 $0
Kevin Hourican EVP & President, CVS Pharmacy 01 Nisan 2019 A 15.237 0 0 $0
Helena Foulkes EVP & President-CVS Pharmacy 16 Şubat 2018 M 45.107 0 0 $0
Robert O. Kraft EVP and President - Omnicare 03 Nisan 2017 A 92.360 0 0 $0
Andrew Sussman EVP, Clinical Services 03 Nisan 2017 A 16.433 0 0 $0
Stephen J Gold EVP & CIO 03 Nisan 2017 A 46.818 0 0 $0
Per Gh Lofberg EVP 02 Ocak 2015 M 23.419 0 0 $0
Mark Cosby EVP & President-CVS/pharmacy 30 Eylül 2013 M 45.955 0 0 $0
Laird Daniels SVP, Cont & Chief Acct Officer 01 Nisan 2013 A 17.845 0 0 $0
Douglas A Sgarro EVP and CLO 11 Mayıs 2012 M 214 0 0 $0
Stuart M Mcguigan SVP and CIO 16 Mart 2012 M 10.967 0 0 $0
Thomas M Ryan Non-Executive Chairman 03 Nisan 2011 F 1.156.702 0 0 $0
Sara Finley SVP, Gen Counsel 18 Şubat 2011 F 29.053 0 0 $0
Michael V Ferdinandi Senior Vice President 19 Ağustos 2009 S 16.021 0 0 $0
Paula A Price Controller 12 Şubat 2008 A 16.498 0 0 $0
Edwin M Crawford Chairman 29 Ekim 2007 A 135.572 0 0 $0
William R Spalding EVP Caremark Pharmacy Services 18 Haziran 2007 M 182 0 0 $0
Gregory S Weishar Vice President 03 Nisan 2006 A 30.161 0 0 $0
Larry D Solberg Senior Vice President 16 Şubat 2006 A 5.978 0 0 $0
ROBBINS LARRY Yönetim kurulu üyesi 21 Mayıs 2026 S 4.824.799 0 8 $-352.750.556
Fernando Aguirre Yönetim kurulu üyesi 21 Mayıs 2026 D 10.513 0 0 $0
Jeffrey R. Balser Yönetim kurulu üyesi 14 Mayıs 2026 A 15.717 0 0 $0
Douglas H. Shulman Yönetim kurulu üyesi 14 Mayıs 2026 A 5.929 0 0 $0
Leslie V Norwalk Yönetim kurulu üyesi 14 Mayıs 2026 A 7.376 0 0 $0
Michael F Mahoney Yönetim kurulu üyesi 14 Mayıs 2026 A 6.345 0 0 $0
Anne A. Finucane Yönetim kurulu üyesi 14 Mayıs 2026 A 591 0 0 $0
John E Gallina Yönetim kurulu üyesi 14 Mayıs 2026 A 582 0 0 $0
Guy P Sansone Yönetim kurulu üyesi 14 Mayıs 2026 A 15.106 0 0 $0
Scott J Kirby Yönetim kurulu üyesi 14 Mayıs 2026 A 14.434 0 0 $0
DECOUDREAUX ALECIA A Yönetim kurulu üyesi 14 Mayıs 2026 A 2.970 0 0 $0
David C Brown II Yönetim kurulu üyesi 14 Mayıs 2026 A 129.316 0 0 $0
Roger N Farah Yönetim kurulu üyesi 30 Kasım 2025 F 19.438 0 0 $0
Mary L Schapiro Yönetim kurulu üyesi 21 Kasım 2024 A 7.585 0 0 $0
Jean Pierre Millon Yönetim kurulu üyesi 21 Kasım 2024 A 4.514 0 0 $0
Nancy Ann Deparle Yönetim kurulu üyesi 21 Kasım 2024 A 34.169 0 0 $0
Edward J Ludwig Yönetim kurulu üyesi 02 Mayıs 2024 P 21.630 0 0 $0
William C Weldon Yönetim kurulu üyesi 17 Kasım 2022 A 1.591 0 0 $0
Tony L White Yönetim kurulu üyesi 11 Mayıs 2022 A 37.852 0 0 $0
David W Dorman Yönetim kurulu üyesi 11 Mayıs 2022 A 109.875 0 0 $0
Larry J Merlo Yönetim kurulu üyesi 31 Mayıs 2021 F 632.313 0 0 $0
Mark T Bertolini Yönetim kurulu üyesi 20 Kasım 2019 A 13.773 0 0 $0
Richard M Bracken Yönetim kurulu üyesi 20 Kasım 2019 A 15.348 0 0 $0
Richard J Swift Yönetim kurulu üyesi 20 Kasım 2019 A 7.336 0 0 $0
Kristen Gibney Williams Yönetim kurulu üyesi 09 Mayıs 2013 A 1.695 0 0 $0
C A Piccolo Yönetim kurulu üyesi 14 Aralık 2012 S 181.461 0 0 $0
Marian L Heard Yönetim kurulu üyesi 08 Kasım 2012 A 11.346 0 0 $0
Edwin M Banks Yönetim kurulu üyesi 15 Mart 2012 M 23.187 0 0 $0
Terrence Murray Yönetim kurulu üyesi 02 Kasım 2011 A 84.140 0 0 $0
Sheli Z Rosenberg Yönetim kurulu üyesi 04 Kasım 2010 A 125.112 0 0 $0
JOYCE WILLIAM H Yönetim kurulu üyesi 04 Kasım 2010 A 18.390 0 0 $0
Roger L Headrick Yönetim kurulu üyesi 23 Mayıs 2007 P 2.200 0 0 $0
Alfred J Verrecchia Yönetim kurulu üyesi 07 Mart 2007 A 0 0 0 $0
Don W Cornwell Yönetim kurulu üyesi 22 Aralık 2006 A · 0 0 $0
Thomas P Gerrity Yönetim kurulu üyesi 09 Kasım 2006 A 68.460 0 0 $0
Stanley P Goldstein Yönetim kurulu üyesi 11 Mayıs 2006 J 590.967 0 0 $0
Terry R Lautenbach Yönetim kurulu üyesi 21 Mayıs 2004 A 27.915 0 0 $0
Chris W Bodine · 18 Şubat 2009 A 23.132 0 0 $0

SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış

ETF sahipliği 157 ETF'ler tarafından tutuluyor

20

Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.

Fon Ağırlık Birimler Tarih itibarıyla Kaynak
IHF · iShares Trust 13,37% 1.839.467 SH 11 Eylül 2026 Günlük
DUSA · Davis Fundamental ETF Trust 5,28% 642.932 NS 31 Temmuz 2026 N-PORT
GEND · Spinnaker ETF Series 4,47% 2.080 NS 31 Temmuz 2026 N-PORT
IYK · iShares Trust 4,25% 617.818 SH 11 Eylül 2026 Günlük
CVGD · Elevation Series Trust 4,14% 54.893 NS 31 Temmuz 2026 N-PORT
PEZ · Invesco Exchange-Traded Fund Trust 3,42% 8.582 SH 01 Ekim 2026 Günlük
FMTM · EA Series Trust 3,17% 76.503 NS 31 Temmuz 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2,83% 2.458 NS 31 Temmuz 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 2,70% 158.312 NS 31 Temmuz 2026 N-PORT
SPDV · ETF Series Solutions 2,29% 28.879 NS 31 Temmuz 2026 N-PORT
VHT · VANGUARD WORLD FUND 1,94% 3.824.297 SH 19 Ağustos 2026 Günlük
FHLC · FIDELITY COVINGTON TRUST 1,92% 605.189 NS 31 Temmuz 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 1,92% 2.169.744 SH 01 Ekim 2026 Günlük
RPV · Invesco Exchange-Traded Fund Trust 1,77% 339.241 SH 01 Ekim 2026 Günlük
REVS · Columbia ETF Trust I 1,68% 53.828 NS 31 Temmuz 2026 N-PORT
IXJ · iShares Trust 1,54% 670.400 SH 11 Eylül 2026 Günlük
CURE · Direxion Shares ETF Trust 1,53% 25.107 NS 31 Temmuz 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,47% 149.525 SH 01 Ekim 2026 Günlük
PWV · Invesco Exchange-Traded Fund Trust 1,41% 298.497 SH 01 Ekim 2026 Günlük
SPVM · Invesco Exchange-Traded Fund Trust 1,39% 21.140 SH 01 Ekim 2026 Günlük
DVY · iShares Trust 1,37% 3.384.928 SH 11 Eylül 2026 Günlük
VLUE · iShares Trust 1,35% 1.359.538 SH 11 Eylül 2026 Günlük
CVAR · ETF Opportunities Trust 1,21% 4.966 NS 31 Temmuz 2026 N-PORT
GURU · Global X Funds 1,19% 6.951 NS 31 Temmuz 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 1,13% 40.514.000 01 Ekim 2026 Günlük
RECS · Columbia ETF Trust I 1,09% 610.992 NS 31 Temmuz 2026 N-PORT
VRP · Invesco Exchange-Traded Fund Trust … 1,06% 31.397.000 01 Ekim 2026 Günlük
FEUS · FlexShares Trust 0,97% 10.395 NS 31 Temmuz 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0,95% 77.895 SH 19 Ağustos 2026 Günlük
EQWL · Invesco Exchange-Traded Fund Trust 0,92% 295.291 SH 01 Ekim 2026 Günlük
FXG · First Trust Exchange-Traded AlphaDE… 0,82% 18.035 NS 31 Temmuz 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0,81% 90.308 SH 01 Ekim 2026 Günlük
LSEQ · Harbor ETF Trust 0,80% 1.171 NS 31 Temmuz 2026 N-PORT
FTLS · First Trust Exchange-Traded Fund III 0,80% 190.028 NS 31 Temmuz 2026 N-PORT
VFMF · VANGUARD WELLINGTON FUND 0,75% 50.750 SH 19 Ağustos 2026 Günlük
MTUM · iShares Trust 0,75% 1.909.551 SH 11 Eylül 2026 Günlük
UPSD · ETF Series Solutions 0,74% 8.286 NS 31 Temmuz 2026 N-PORT
FBCV · FIDELITY COVINGTON TRUST 0,72% 12.142 NS 31 Temmuz 2026 N-PORT
WLDR · Two Roads Shared Trust 0,71% 6.228 NS 31 Temmuz 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0,70% 20.507.000 01 Ekim 2026 Günlük
BSCR · Invesco Exchange-Traded Self-Indexe… 0,67% 31.259.000 01 Ekim 2026 Günlük
CATH · Global X Funds 0,63% 78.905 NS 31 Temmuz 2026 N-PORT
GSY · Invesco Actively Managed Exchange-T… 0,63% 24.935.000 01 Ekim 2026 Günlük
SPMO · Invesco Exchange-Traded Fund Trust … 0,62% 1.682.074 SH 01 Ekim 2026 Günlük
MGV · VANGUARD WORLD FUND 0,62% 801.966 SH 19 Ağustos 2026 Günlük
LSVD · ADVISORS' INNER CIRCLE FUND 0,58% 36.106 NS 31 Temmuz 2026 N-PORT
FFLV · FIDELITY COVINGTON TRUST 0,57% 900 NS 31 Temmuz 2026 N-PORT
PFIG · Invesco Exchange-Traded Fund Trust … 0,55% 715.000 01 Ekim 2026 Günlük
VYM · VANGUARD WHITEHALL FUNDS 0,55% 5.122.611 SH 19 Ağustos 2026 Günlük
PDP · Invesco Exchange-Traded Fund Trust 0,51% 86.857 SH 01 Ekim 2026 Günlük
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0,50% 40.184 NS 31 Temmuz 2026 N-PORT
VTV · VANGUARD INDEX FUNDS 0,49% 12.134.319 SH 19 Ağustos 2026 Günlük
DFUV · Dimensional ETF Trust 0,48% 710.848 NS 31 Temmuz 2026 N-PORT
DFLV · Dimensional ETF Trust 0,47% 302.533 NS 31 Temmuz 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0,46% 529.245 SH 01 Ekim 2026 Günlük
BSCT · Invesco Exchange-Traded Self-Indexe… 0,46% 13.367.000 30 Eylül 2026 Günlük
IWX · iShares Trust 0,45% 185.452 SH 11 Eylül 2026 Günlük
VOOV · VANGUARD ADMIRAL FUNDS 0,45% 293.814 SH 19 Ağustos 2026 Günlük
IVE · iShares Trust 0,41% 2.119.397 SH 11 Eylül 2026 Günlük
DIVB · iShares Trust 0,41% 87.120 SH 11 Eylül 2026 Günlük
CHRI · Global X Funds 0,41% 310 NS 31 Temmuz 2026 N-PORT
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0,40% 17.702 NS 31 Temmuz 2026 N-PORT
IUSV · iShares Trust 0,39% 1.116.077 SH 11 Eylül 2026 Günlük
VONV · VANGUARD SCOTTSDALE FUNDS 0,37% 774.792 SH 19 Ağustos 2026 Günlük
ESG · FlexShares Trust 0,37% 4.650 NS 31 Temmuz 2026 N-PORT
ILCV · iShares Trust 0,35% 49.213 SH 11 Eylül 2026 Günlük
IWD · iShares Trust 0,33% 2.852.019 SH 11 Eylül 2026 Günlük
GLBL · Pacer Funds Trust 0,32% 34 NS 31 Temmuz 2026 N-PORT
EGLE · Global X Funds 0,31% 65 NS 31 Temmuz 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0,30% 57.429 SH 19 Ağustos 2026 Günlük
OEF · iShares Trust 0,26% 540.125 SH 11 Eylül 2026 Günlük
INFO · Harbor ETF Trust 0,25% 20.350 NS 31 Temmuz 2026 N-PORT
MGC · VANGUARD WORLD FUND 0,25% 255.122 SH 19 Ağustos 2026 Günlük
ESGV · VANGUARD WORLD FUND 0,23% 290.253 SH 19 Ağustos 2026 Günlük
TOPC · iShares Trust 0,23% 777 SH 11 Eylül 2026 Günlük
IWL · iShares Trust 0,22% 49.933 SH 11 Eylül 2026 Günlük
VV · VANGUARD INDEX FUNDS 0,21% 1.490.162 SH 19 Ağustos 2026 Günlük
XYLD · Global X Funds 0,21% 64.877 NS 31 Temmuz 2026 N-PORT
XTR · Global X Funds 0,21% 96 NS 31 Temmuz 2026 N-PORT
XVV · iShares Trust 0,21% 14.653 SH 11 Eylül 2026 Günlük
EUSA · iShares, Inc. 0,21% 41.666 SH 11 Eylül 2026 Günlük
XRMI · Global X Funds 0,21% 990 NS 31 Temmuz 2026 N-PORT
PTLC · Pacer Funds Trust 0,21% 64.355 NS 31 Temmuz 2026 N-PORT
DFSU · Dimensional ETF Trust 0,21% 44.781 NS 31 Temmuz 2026 N-PORT
BBUS · J.P. Morgan Exchange-Traded Fund Tr… 0,20% 174.338 NS 31 Temmuz 2026 N-PORT
BKLC · BNY Mellon ETF Trust 0,20% 106.735 NS 31 Temmuz 2026 N-PORT
XYLG · Global X Funds 0,20% 1.250 NS 31 Temmuz 2026 N-PORT
VOTE · TCW ETF Trust 0,20% 21.382 NS 31 Temmuz 2026 N-PORT
ADME · ETF Series Solutions 0,20% 5.697 NS 31 Temmuz 2026 N-PORT
XCLR · Global X Funds 0,20% 69 NS 31 Temmuz 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0,20% 33.144.255 SH 19 Ağustos 2026 Günlük
TOV · EA Series Trust 0,20% 5.061 NS 31 Temmuz 2026 N-PORT
ACIO · ETF Series Solutions 0,20% 44.949 NS 31 Temmuz 2026 N-PORT
LRGF · iShares Trust 0,20% 76.567 SH 11 Eylül 2026 Günlük
QVML · Invesco Exchange-Traded Fund Trust … 0,20% 37.793 SH 01 Ekim 2026 Günlük
DFUS · Dimensional ETF Trust 0,19% 389.482 NS 31 Temmuz 2026 N-PORT
VOXP · Advisors Series Trust 0,19% 108 NS 31 Temmuz 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0,19% 4.814 NS 31 Temmuz 2026 N-PORT
VONE · VANGUARD SCOTTSDALE FUNDS 0,19% 212.337 SH 19 Ağustos 2026 Günlük
QDPL · Pacer Funds Trust 0,19% 30.732 NS 31 Temmuz 2026 N-PORT
EVUS · iShares Trust 0,19% 7.499 SH 11 Eylül 2026 Günlük
IVV · iShares Trust 0,19% 16.082.099 SH 11 Eylül 2026 Günlük
RSP · Invesco Exchange-Traded Fund Trust 0,18% 2.050.840 SH 01 Ekim 2026 Günlük
SIZE · iShares Trust 0,18% 8.166 SH 11 Eylül 2026 Günlük
FEX · First Trust Exchange-Traded AlphaDE… 0,18% 27.242 NS 31 Temmuz 2026 N-PORT
ILCB · iShares Trust 0,18% 24.548 SH 11 Eylül 2026 Günlük
VTI · VANGUARD INDEX FUNDS 0,18% 40.509.855 SH 19 Ağustos 2026 Günlük
VTHR · VANGUARD SCOTTSDALE FUNDS 0,18% 108.067 SH 19 Ağustos 2026 Günlük
IWB · iShares Trust 0,17% 888.287 SH 11 Eylül 2026 Günlük
IYY · iShares Trust 0,17% 54.746 SH 11 Eylül 2026 Günlük
USCL · iShares Trust 0,17% 50.655 SH 11 Eylül 2026 Günlük
FTA · First Trust Exchange-Traded AlphaDE… 0,17% 22.631 NS 31 Temmuz 2026 N-PORT
PBP · Invesco Exchange-Traded Fund Trust 0,17% 7.610 SH 01 Ekim 2026 Günlük
IWV · iShares Trust 0,17% 354.060 SH 11 Eylül 2026 Günlük
TILT · FlexShares Trust 0,17% 34.918 NS 31 Temmuz 2026 N-PORT
DCOR · Dimensional ETF Trust 0,17% 53.112 NS 31 Temmuz 2026 N-PORT
DFAU · Dimensional ETF Trust 0,17% 197.043 NS 31 Temmuz 2026 N-PORT
PBUS · Invesco Exchange-Traded Fund Trust … 0,17% 220.176 SH 01 Ekim 2026 Günlük
ITOT · iShares Trust 0,17% 1.661.154 SH 11 Eylül 2026 Günlük
HCMT · Direxion Shares ETF Trust 0,16% 8.880 NS 31 Temmuz 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,16% 15.076 SH 01 Ekim 2026 Günlük
ACVF · ETF Opportunities Trust 0,16% 2.271 NS 31 Temmuz 2026 N-PORT
DYNF · BlackRock ETF Trust 0,16% 675.214 SH 11 Eylül 2026 Günlük
SPXL · Direxion Shares ETF Trust 0,15% 99.749 NS 31 Temmuz 2026 N-PORT
TOK · iShares Trust 0,14% 3.579 SH 11 Eylül 2026 Günlük
PHDG · Invesco Actively Managed Exchange-T… 0,14% 1.007 SH 01 Ekim 2026 Günlük
URTH · iShares, Inc. 0,13% 114.536 SH 11 Eylül 2026 Günlük
OMFL · Invesco Exchange-Traded Self-Indexe… 0,13% 70.355 SH 01 Ekim 2026 Günlük
DFAC · Dimensional ETF Trust 0,12% 539.188 NS 31 Temmuz 2026 N-PORT
ACWI · iShares Trust 0,12% 406.018 SH 11 Eylül 2026 Günlük
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,11% 1.069.623 SH 19 Ağustos 2026 Günlük
DXUV · Dimensional ETF Trust 0,10% 5.157 NS 31 Temmuz 2026 N-PORT
QLC · FlexShares Trust 0,09% 8.960 NS 31 Temmuz 2026 N-PORT
FAB · First Trust Exchange-Traded AlphaDE… 0,08% 1.368 NS 31 Temmuz 2026 N-PORT
CRBN · iShares Trust 0,05% 6.619 SH 11 Eylül 2026 Günlük
FBCG · FIDELITY COVINGTON TRUST 0,05% 35.048 NS 31 Temmuz 2026 N-PORT
GLOF · iShares Trust 0,02% 478 SH 11 Eylül 2026 Günlük
LGDX · Tidal Trust III 0,02% 251 NS 31 Temmuz 2026 N-PORT
GTOS · Invesco Actively Managed Exchange-T… 0,02% 21.000 01 Ekim 2026 Günlük
GTO · Invesco Actively Managed Exchange-T… 0,01% 419.000 01 Ekim 2026 Günlük
PEVC · Pacer Funds Trust 0,01% 3 NS 31 Temmuz 2026 N-PORT
NEAR · iShares U.S. ETF Trust 0,01% 600.000 SH 11 Eylül 2026 Günlük
DFVX · Dimensional ETF Trust 0,01% 517 NS 31 Temmuz 2026 N-PORT
BIV · VANGUARD BOND INDEX FUNDS · · 15 Temmuz 2026 Günlük
BLV · VANGUARD BOND INDEX FUNDS · · 15 Temmuz 2026 Günlük
BSV · VANGUARD BOND INDEX FUNDS · · 15 Temmuz 2026 Günlük
BND · VANGUARD BOND INDEX FUNDS · · 15 Temmuz 2026 Günlük
VCRB · VANGUARD MALVERN FUNDS · · 15 Temmuz 2026 Günlük
VPLS · VANGUARD MALVERN FUNDS · · 15 Temmuz 2026 Günlük
VSDB · VANGUARD MALVERN FUNDS · · 15 Temmuz 2026 Günlük
VGMS · VANGUARD MALVERN FUNDS · · 15 Temmuz 2026 Günlük
VCSH · VANGUARD SCOTTSDALE FUNDS · · 15 Temmuz 2026 Günlük
VCIT · VANGUARD SCOTTSDALE FUNDS · · 15 Temmuz 2026 Günlük
VCLT · VANGUARD SCOTTSDALE FUNDS · · 15 Temmuz 2026 Günlük
VTC · VANGUARD SCOTTSDALE FUNDS · · 30 Temmuz 2026 Günlük
BNDW · VANGUARD SCOTTSDALE FUNDS · · 30 Temmuz 2026 Günlük
VCEB · VANGUARD WORLD FUND · · 30 Temmuz 2026 Günlük

CVS Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel

21
derecelendirme · 33 analist AL
Medyan hedef $116.00 +34,2%
8 24,2% Güçlü Al
20 60,6% Al
5 15,2% Tut
0 0,0% Sat
0 0,0% Güçlü Sat

12 Aylık Fiyat Hedefi

25 analist · 2026-09-28

Ortalama hedef $116.28 +34,5%

← Tüm hedeflerin altında Mevcut fiyat $86.46
Düşük$103.00 Ortalama$116.28 Yüksek$148.00

Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı

22

Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.

Hisse Sembolü Piyasa Değeri P/E Gelir YoY Net Kar Marjı ROE Brüt Kar Marjı
CVS $100.87B 57.1 7.8% 0.44% 2.4% ·
CI $72.51B 12.4 11.2% 2.2% 14.4% ·
DGX $19.09B 19.8 11.8% 9.0% 14.2% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
GH $13.34B -30.8 32.9% -42.4% 205.7% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
BTSG $7.20B 43.0 28.2% 1.5% 10.8% 11.8%
DVA $7.79B 11.5 6.5% 5.5% -281.8% ·
HNGE $0 -6.0 50.6% -89.9% -299.8% 79.7%
HIMS · 63.7 59.0% 5.5% 23.3% 73.8%
CHE · 23.3 4.1% 10.5% 24.4% ·

Son Haberler Bu şirketten bahseden son manşetler

23

İşlem Sinyalleri Giriş fiyatı ve risk/ödül oranı ile son alım/satım sinyalleri

25

Şu anda açık sinyal yok — hiçbir kart dolu değil ve bu dürüstçe.

Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar

26

Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.

Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.

Kaynak: SEC 10-Q dosyalandı Ağu 5, 2026